Table 3. Outcome measures for patients... | American Society of Hematology

Table 3.

Outcome measures for patients receiving rituximab prophylaxis

Measure	Total (N = 76)			Standard dose (n = 24)			Reduced dose (n = 19)			Intermediate dose (n = 17)			Other doses (n = 16)
Measure	n/N	%	Months (range)	n/N	%	Months (range)	n/N	%	Months (range)	n/N	%	Months (range)	n/N	%	Months (range)
No. of patients in CR (ADAMTS13 ≥60%)	60/76	78.9		18/24	75		16/19	84.2		12/17	70.6		14/16	87.5
No. of patients in PR (ADAMTS13 30%-59%)	10/76	13.2		3/24	12.5		2/19	10.5		4/17	23.5		1/16	6.25
No. of patients achieving at least a PR (ADAMTS13 ≥30%)	70/76	92.1		21/24	87.5		18/19	94.7		16/17	94.1		15/16	93.4
Time to ADAMTS13 recovery			1 (<1-5)			1 (<1-5)			2 (<1-4)			1 (<1-3)			2 (<1-4)
Median overall follow-up			15 (1-141)			17.5 (1-141)			25 (9-43)			10 (3-20)			21 (3-112)
No. of patients requiring re-treatment	38/76	50		12/24 *	50		14/19 *	73.7		3/17	17.6		10/16	62.5
Re-treatment episodes per year	0.25			0.17†			0.38†			0.20			0.29

Measure	Total (N = 76)			Standard dose (n = 24)			Reduced dose (n = 19)			Intermediate dose (n = 17)			Other doses (n = 16)
Measure	n/N	%	Months (range)	n/N	%	Months (range)	n/N	%	Months (range)	n/N	%	Months (range)	n/N	%	Months (range)
No. of patients in CR (ADAMTS13 ≥60%)	60/76	78.9		18/24	75		16/19	84.2		12/17	70.6		14/16	87.5
No. of patients in PR (ADAMTS13 30%-59%)	10/76	13.2		3/24	12.5		2/19	10.5		4/17	23.5		1/16	6.25
No. of patients achieving at least a PR (ADAMTS13 ≥30%)	70/76	92.1		21/24	87.5		18/19	94.7		16/17	94.1		15/16	93.4
Time to ADAMTS13 recovery			1 (<1-5)			1 (<1-5)			2 (<1-4)			1 (<1-3)			2 (<1-4)
Median overall follow-up			15 (1-141)			17.5 (1-141)			25 (9-43)			10 (3-20)			21 (3-112)
No. of patients requiring re-treatment	38/76	50		12/24 *	50		14/19 *	73.7		3/17	17.6		10/16	62.5
Re-treatment episodes per year	0.25			0.17†			0.38†			0.20			0.29

n/N, number/total.

There was no significant difference in proportion of patients requiring re-treatment in standard- vs reduced-dose groups (P = .13).

The rate of re-treatment was significantly lower in the standard- vs reduced-dose group (0.17 vs 0.38 episodes per year, respectively; P = .039).